期刊文献+

糖尿病高血压和糖尿病肾病患者血清MMP-2及TIMP-1的表达及意义 被引量:2

Clinical Significence and Serum MMP-2 and TIMP-1 with Diabetic Hypertention and Diabetic Nephropathy
下载PDF
导出
摘要 为了探讨MMP-2、TIMP-1在DMEH和DN发病中的意义,随机收集T2DM患者146例,其中SDM57例,DMEH38例,DN51例,健康对照38例。用ELISA法测定MMP-2、TIMP-1的含量。结果显示,DM患者尤其是DMEH和DN患者血清MMP-2明显低于健康对照组,P均<0.01,且随病情发展呈逐渐降低趋势。而血清TIMP-1随病情的发展则呈现明显的上升趋势,SDM、DMEH组和DN组与健康对照组比较,分别为P<0.05,P<0.01和P<0.01。因此,MMP-2和TIMP-1可能参与了DMEH和DN的发生发展过程,定期检测DM患者血清MMP-2和TIMP-1的含量变化有助于DM并发症的早期诊断和疗效观察。 To find out the regularity of the changing of serum matrix metalloproteinase-2(MMP-2) and tissue inhibitor of metalloproteinase -1(TIMP-1) in the patients with diabetes type 2. To discuss the roles played by MMP-2 and TIMP-1 in the patients with high blood pressure and kidney harm related to diabetes.Randomly collected 146 cases of patients with diabetes type 2, in which 57 cases were the diabetic patients without other syndromes,38 cases were the diabetic patients with hypertension,51 cases were the diabetic patients with nephropathy. And 38 cases were the healthy ones as contrast. The levels of serum MMP-2 and TIMP-1 were measured by ELISA.The content of MMP-2 in the diabetic patients was significantly lower than that in the healthy ones, and MMP-2 in the diabetic patients with high blood pressure and nephropathy was even much lower, P〈0.01,P〈0.01;and was getting lower with the development of the disease.Meanwhile, TIMP-1 was getting higher with the development of the disease, P values were respectively P〈0.05,P〈0.01 and P〈0.01 compared with the contrast to the groups of the cases without other syndromes, with high blood pressure and with nephropathy.MMP-2 and TIMP-1 were likely to be the participants in the process of occurrence and development of diabetic high blood pressure and kidney nephropathy. Measuring the content of MMP-2 and TIMP-1 could properly provide a new reference to the early diagnoses and treatments of the diabetes and its syndrome.
出处 《医学与哲学(B)》 2008年第2期32-33,39,共3页 Medicine & Philosophy(B)
基金 河北省科学技术研究与发展指导计划项目 项目编号:072761664
  • 相关文献

参考文献6

二级参考文献25

  • 1谢明智 刘海帆 等.实验性肥胖及糖尿病大鼠[J].药学学报,1985,20:801-801.
  • 2Okazaki L,Wada N,Nakano M,et al.Difference in gene expression for matrix matalloproteinase-Ⅰ between early and advanced hepatocellular carcinomas[J].Hepatology,1997,26(6):1521.
  • 3Arthur MJP,Murawaki Y.Serum matalloproteinase-Ⅰ in patients with chronic viral hepatitis[J].J Gastroenterol Hepatol,1999,14(2):138.
  • 4Murawaki Y,Yamada S,Ikuta y,et al.Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease[J].J Hepatol,1999,30(6):1090.
  • 5Murawaki Y,Ikuta Y,Idobe Y,et al.Tissue inhibitor of metalloproteinase-I in the liver of patients with chronic liver disease[J].J Hepatal,1997,26(6):1213.
  • 6Ueno T,Tamaki S,Sugawara H,et al.Significance of serum tissue inhibitor of metalloproteinase-I in various liver disease[J].J Hepatal,1996,24:177.
  • 7Laviades C,Varo N,Fernander J,et al.Abnormalities of the extracellular degradation of collagen type Ⅰ in essential hypertension[J].Circulation,1998,98(6):535.
  • 8Fisher E J,Endocrinol Metabol,1997年,4卷,371页
  • 9Leehey D J,Diabetes,1995年,44卷,929页
  • 10谢明智,药学学报,1985年,20卷,801页

共引文献44

同被引文献15

  • 1沈庆乐,张存琪.血清基质金属蛋白酶与糖尿病血管病变的关系[J].微循环技术杂志(临床与实验),2004,8(5):349-349. 被引量:19
  • 2侯振江,张宗英.基质金属蛋白酶类测定的临床应用[J].中国实验诊断学,2006,10(2):216-218. 被引量:8
  • 3Diamant M,Hanemaaijier R,Verheijen JH,et al.Elevatedmatrix metalloproteinase-2 and-9 in urne,but not in serum,are markers of type 1 diabetic nephropathy[J].Diabet Med,2002,18 (5):423-424.
  • 4Marchetti D,Reiland J,Erwin B,et al. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues [J]. Int J Cancer,2003,104(2) :167-174.
  • 5Vaday G G, Lider O. Extracellular matrix moie-ties, cytokines, and enzymes:dynamic effects on immune cell behavion and inflam- mation[J]. J Leukoc Biol,2000,67:149-159.
  • 6Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase : gene cloning, expression and function in tumor progression and me- tastasis [J]. Nat Med,1999,5(7):793-802.
  • 7Parish C R, Freeman C, Hulett M D. Heparanase: a key enzyme involved in cell invasionBiochim[J]. Biophys Acta, 2001,1471 (3) : M99-108.
  • 8Gingis-Velitski S,Zelser A,F|ugelman M Y,et al. Heparanase induces cell migration via protein kinase B/Akt activation [J]. J Biol Chem, 2004, 279 (11):23536-23541.
  • 9Barash U, Cohen-Kaplan V, Arvaatz, et al. A novel human heparanase splice variant, T5, endowed with protumorigenic char- acteristics[J]. J FASEB,2010,24 (4) : 1239-1248.
  • 10Takaoka M, Naomoto Y,Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric caneers[J]. J Lab Invest, 2003,83:613-622.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部